"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
| Descriptor ID |
D050130
|
| MeSH Number(s) |
E02.095.601
|
| Concept/Terms |
Oncolytic Virotherapy- Oncolytic Virotherapy
- Oncolytic Virotherapies
- Virotherapies, Oncolytic
- Virotherapy, Oncolytic
- Oncolytic Virus Therapy
- Oncolytic Virus Therapies
- Therapies, Oncolytic Virus
- Therapy, Oncolytic Virus
- Virus Therapies, Oncolytic
- Virus Therapy, Oncolytic
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".
This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 0 | 6 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 1 | 4 |
| 2021 | 5 | 1 | 6 |
| 2022 | 6 | 0 | 6 |
| 2023 | 5 | 0 | 5 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 3 | 5 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.
-
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment. Nat Cancer. 2026 May; 7(5):723-739.
-
Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. J Neurooncol. 2026 Feb 25; 177(1).
-
Translational advancement of immunotherapeutics against pediatric central nervous system tumors. Adv Cancer Res. 2025; 167:327-358.
-
The promise of immunotherapy for central nervous system tumours. Nat Rev Immunol. 2026 Mar; 26(3):213-229.
-
Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform. Adv Sci (Weinh). 2025 Oct; 12(38):e15356.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 07; 643(8070):219-229.
-
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24; 16(1):3874.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 12 09; 12(12).
-
Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. Mol Cancer Ther. 2024 Sep 04; 23(9):1273-1281.
-
Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms. Int J Mol Sci. 2024 Jun 19; 25(12).